Gibb River Diamonds Limited (ASX:GIB) Secures Mining Lease for Edjudina Project
Gibb River Diamonds Limited (ASX:GIB) secures mining lease for Edjudina Gold Project, advancing monetisation of the Neta resource.
Tag: Regulatory News & Compliance
The Star Entertainment Group Ltd (ASX:SGR) Receives $650m Debt Refinancing Proposal
Star Entertainment Group (ASX:SGR) receives a $650 million debt refinancing proposal, highlighting ongoing liquidity challenges.
Diablo Resources Limited (ASX:DBO) Requests Trading Halt Pending Announcement
Diablo Resources Limited (ASX:DBO) has requested a trading halt pending an announcement on a potential project acquisition and capital raising.
Mont Royal Resources Limited (ASX:MRZ) Suspended from Quotation
Mont Royal Resources Limited (ASX:MRZ) suspends its securities from quotation pending a proposed re-compliance transaction.
Desert Metals Limited (ASX:DM1) Announces Trading Halt
Desert Metals Limited (ASX:DM1) requests a trading halt pending an upcoming announcement, potentially related to a capital raise.
Artemis Resources Limited (ASX:ARV) Clarifies Permitting for Radio Hill
Artemis Resources (ASX:ARV) clarifies permitting activities for the Radio Hill processing plant and updates on the Carlow Castle Mineral Resource Estimate.
ACORN CAPITAL INVESTMENT FUND LIMITED (ASX:ACQ) Suspended from Quotation
ACORN CAPITAL INVESTMENT FUND LIMITED (ASX:ACQ) is suspended from quotation for not lodging the required periodic report by the due date.
Neurizon Therapeutics Limited (ASX:NUZ) Receives FDA Guidance on NUZ-001 IND Application
Neurizon Therapeutics Limited (ASX:NUZ) receives FDA guidance on its IND application for NUZ-001, requesting additional animal exposure data.
Smart Parking Limited (ASX:SPZ) Requests Trading Halt
Smart Parking Limited (ASX:SPZ) requests a trading halt until 19 February 2025 pending its accelerated entitlement offer outcome.
Recce Pharmaceuticals (ASX:RCE) Reports Successful Phase II Trial Results
Recce Pharmaceuticals (ASX:RCE) reports successful Phase II trial of RECCE®327 Gel, advancing to Phase III for ABSSSI treatment.